Trending...
- Yet another EU country´s Data Protection Authority makes it official! Google Analytics is out!
- SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Yatsen Holding Limited with Losses of $100,000 to Contact the Firm
- SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Barclays PLC with Losses of $100,000 to Contact the Firm
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on August 10, 2022, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 28,250 shares of common stock and 14,100 restricted stock units ("RSUs") to eight new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price per share equal to $24.93 per share, Mirum's closing trading price on August 10, 2022, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum's 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum's approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Please view the warnings and precautions available in the Prescribing information or, for more information, visit LIVMARLI.com.
More on The Californer
Mirum's late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.
Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome.
Mirum's second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis, the OHANA Phase 2b clinical trial for pregnant women with intrahepatic cholestasis of pregnancy, and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.
More on The Californer
Learn more about Mirum by visiting www.mirumpharma.com. Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.
Contacts
Investor Contacts:
Ian Clements, Ph.D.
ir@mirumpharma.com
Sam Martin
Argot Partners
ir@mirumpharma.com
Media Contact:
Erin Murphy
media@mirumpharma.com
Each stock option has an exercise price per share equal to $24.93 per share, Mirum's closing trading price on August 10, 2022, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum's 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum's approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Please view the warnings and precautions available in the Prescribing information or, for more information, visit LIVMARLI.com.
More on The Californer
- Dynamic Design Solutions Announces Best Sales Year on Record in Back-to-Back Fiscal Years
- Enersponse and NexRev Partner to Empower Customers With Access to Energy Management Solutions
- PARAMOUNT CONSUMER PRODUCTS AND NICKELODEON ANNOUNCE LAUNCH OF GLOBAL OCEAN CONSERVATION AND SUSTAINABILITY INITIATIVE SPONGEBOB SQUAREPANTS: OPERATION SEA CHANGE
- BookingPal Integrates Airbnb Reviews to Help Property Managers Improve Vacation Rental Rankings
- Sydney Brachytherapy Group is the first private non-melanoma skin cancer clinic in Sydney to offer OncoBeta's Rhenium-SCT
Mirum's late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.
Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome.
Mirum's second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis, the OHANA Phase 2b clinical trial for pregnant women with intrahepatic cholestasis of pregnancy, and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.
More on The Californer
- PermaTherm Announces Panels Delivered Quickly Program
- General Inception Creates First-Ever "Igniter" for New Company Formation
- ASI Hosts 24th Annual iNNOVATIONS Conference and Announces Award Winners
- NuVasive Announces Agenda for Investor Day 2022
- Lionrock Adds Ketamine Assisted Psychotherapy Program to State-of-the-Art Treatment Offerings for Substance Use Disorder
Learn more about Mirum by visiting www.mirumpharma.com. Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.
Contacts
Investor Contacts:
Ian Clements, Ph.D.
ir@mirumpharma.com
Sam Martin
Argot Partners
ir@mirumpharma.com
Media Contact:
Erin Murphy
media@mirumpharma.com
Filed Under: Business
0 Comments
Latest on The Californer
- Water Reclamation Facility in Moorpark informing future drought resilience
- Asian Hall of Fame Announces Induction 2022
- State Gives $130 Million Boost to Projects Essential to Reliabilty of Southern California's Water Supply
- Distroller Donates Neonate Babies to NICU Families for NICU Sibling Support Day on Sept. 29
- California: On the Record with Governor Gavin Newsom: Saving Water & Building a More Resilient Future
- ATEN Technology Renovates the Desktop for the Hybrid Work Challenge with New KVM Switch
- Experienced Intellectual Property Attorney Christopher Franich Joins Snell & Wilmer's SD Office
- Triunfo Water & Sanitation District Board Approves Reducing Sprinkler Irrigation Time
- Edge AI Innovator Femtosense Raises $8 Million Series A Funding
- CHIRLA, IMMIGRANT RIGHTS GROUPS MOBILIZE IN SUPPORT OF BILL TO EXPAND A PATHWAY FOR RESIDENCY FOR MILLIONS OF LONG-TERM RESIDENTS.
- BEAR Technologies Successfully Completes 2022 SOC 2 Type II Audit
- Exterro Launches FTK® Suite 7.6, Introducing Mobile Parsing, Automation Capabilities, And Industry-First Remote Endpoint Triage
- Lassen Therapeutics Commences Dosing in Phase 1 Clinical Study of LASN01, a First-in-Class Interleukin-11 Receptor-Blocking Antibody
- Honda Advances Support of Hispanic Scholarship Fund with $1 Million Donation
- Re-Introducing Gigahurtz, DJ and Producer
- Pureboost, Amazon's #1 Selling Clean Energy Drink, Raises Over $2M+ Within Hours of Launching Community Round to the Public on Wefunder's Community Investment Platform
- Creating a Telegram sticker pack for brand advertising
- Leopard Imaging to Showcase at VISION in Stuttgart with 2D and 3D Depth Cameras Empowered by onsemi
- Shana Tovah! Happy Rosh Hashanah!
- Tigo Energy Surpasses One-Terawatt Hour of Monitored Solar PV Energy in Europe